Index

Note: Page numbers of article titles are in boldface type.

A

Adjuvant chemotherapy, for locally advanced resectable oral and maxillofacial tumors, 164
Age, and increasing predilection to HNSCC, 125–126
Alcohol, as risk factor for HNSCC, 124
Anti-resorptive medications. See also Bisphosphonates.
osteonecrosis of the jaws due to, 171–191
higher incidence of in patients with cancer, 174–177
in patients without cancer naive to anti-resorptive medications, 172–174
reconstruction of mandibular segmental defects, 184–188
resection as first-line therapy for, 180–184
risk to tori and exostoses, 177–180

Autofluorescence tissue imaging, for screening of HNSCC and precursors, 130–131

B

Biomarkers, prognostic, for HNSCC, 138–139
Biopsy, of HNSCC, 133
sentinel lymph node, in evaluation of neck for nodal metastases, 217
Bisphosphonates. See also Anti-resorptive medications.
role in medical oncology, 231–237
administration and side effects, 232
associated risk of jaw bone necrosis with, 234–235
in metabolic disorders, 233
in multiple myeloma, 232–233
in solid tumors, 233
mechanism of action, 231–232
other bone-modifying agents, 233–234
types of, 232

Brachial plexus, MRI in diagnosis of injuries and masses, 267

C

Carcinoma of unknown primary, evaluation and staging of neck in patients with, 213–214
Chemoradiation therapy. See also Chemotherapy and Radiation therapy.
oral surgery in patients undergoing, 193–207
after, prevention and treatment of osteonecrosis of jaw bone, 201–202
dental implant placement, 203–205

Chemotherapy. See also Chemoradiation therapy.
oral surgery in irradiated jaws, 202
prophylactic hyperbaric oxygen therapy, 202–203
tumors, 200–201
chemotherapy, 194
epidemiology, 194
patient management during, 198–200
mucositis, 198–199
myelosuppression, 198
neurotoxicity and taste alteration, 199–200
xerostomia, 200
preparations before start of therapy, 195–198
in patients receiving chemotherapy, 195
in patients receiving radiation therapy, 195–198
radiation therapy, 194–195

Dental implant placement, after radiation therapy to head and neck region, 203–205
Diagnostics, in head and neck cancer, 123–141
computed tomography (CT), in evaluation of neck for nodal metastases, 214–216
Diagnostics (continued)
imaging, magnetic resonance imaging, 253–269
nuclear medicine studies, 239–245
prediction of prognosis, treatment response, and survival, 133–139
biomarkers, 138–139
biopsy, 133
histologic prognosticators, 136–138
histologic subtypes, 133–136
immunohistochemistry, 138
molecular alterations, 139

Drug-induced osteonecrosis of the jaw, PET imaging in, 243–244
Dyskeratosis congenita, as risk factor for HNSCC, 125

E
Epidemiologic trends, in head and neck cancer, 123–141
age, sex, and race predilection, 125–126
anatomic sites of HNSCC, 126
mouth, 126
tongue, 126
diseases and syndromes associated with increased risk for, 125
Fanconi anemia and dyskeratosis congenita, 125
Plummer-Vinson, 125
incidence, 123–124
oral epithelial dysplasia, 131–133
precursor lesions of HNSCC, 126–129
erythroplakia, 129
leukoplakia, 126–128
oral lichen planus, 129
oral submucous fibrosis, 129
proliferative verrucous leukoplakia, 128
risk factors for, 124–125
HPV, 124–125
other contributing factors, 125
tobacco and alcohol, 124
Epidermal growth factor receptor (EGFR), as prognostic marker for HNSCC, 139
role of inhibitors of, 165
Erythroplakia, as precursor of HNSCC, 128
Extracapsular extension, in histologic grading of HNSCC, 137–138

F
Fanconi anemia, as risk factor for HNSCC, 125
Fibrosis, oral submucous, as precursor of HNSCC, 128

G
Gender, and increasing predilection to HNSCC, 125–126
Giant cell tumor, of the jaws, chemotherapy for, 167
Grading, histologic, of HNSCC, 136–138

H
Head and neck pathologies, anti-resorptive osteonecrosis of the jaws, 171–191
bisphosphonate-related osteonecrosis of jaw, 231–237
chemotherapy for oral and maxillofacial tumors, 163–169
epidemiologic trends and aids in diagnosis of HNSCC, 123–141
evaluation and staging of neck in patients with malignant disease, 207–221
MRI in diagnosis of, 253–269
nuclear medicine imaging in diagnosis of, 239–245
oral surgery in patients undergoing chemoradiation therapy, 193–207
pharmacologic modalities for osteoradionecrosis of jaw, 247–252
pitfalls in determining surgical margins, 151–162
radiation therapy for oral and maxillofacial tumors and dose mapping, 223–229
staged mandibular reconstruction, porous space maintainers in, 143–149
Head and neck squamous cell carcinoma (HNSCC), epidemiologic trends and aids in diagnosis of, 123–141
age, sex, and race predilection, 125–126
anatomic sites of HNSCC, 126
mouth, 126
tongue, 126
diseases and syndromes associated with increased risk for, 125
Fanconi anemia and dyskeratosis congenita, 125
Plummer-Vinson, 125
incidence, 123–124
oral epithelial dysplasia, 131–133
precursor lesions of HNSCC, 126–129
erthroplakia, 129
leukoplakia, 126–128
oral lichen planus, 129
oral submucous fibrosis, 129
proliferative verrucous leukoplakia, 128
risk factors for, 124–125
HPV, 124–125
other contributing factors, 125
tobacco and alcohol, 124
Epidermal growth factor receptor (EGFR), as prognostic marker for HNSCC, 139
role of inhibitors of, 165
Erythroplakia, as precursor of HNSCC, 128
Extracapsular extension, in histologic grading of HNSCC, 137–138

Index
Index

other contributing factors, 125
tobacco and alcohol, 124
Histologic subtypes, of HNSCC, 133–136
conventional/keratinizing, 133
HPV-associated, 133–134
papillary squamous carcinoma, 134, 136
sarcomatoid squamous carcinoma, 136
spindled cell carcinoma, 136
verrucous carcinoma, 134
HNSCC. See Head and neck cancers.
Human papillomavirus (HPV), as prognostic
biomarker for HNSCC, 138–139
as risk factor for HNSCC, 124
Hyperbaric oxygen therapy, for osteonecrosis of the
jaw, 249–250
prophylactic, in patients receiving radiation
therapy, 203
Imaging, MRI in diagnosis of head and neck disease, 253–269
nuclear medicine studies in diagnosis of head and
neck disease, 239–245
of neck in patients with malignant disease, 214–217
Immunohistochemistry, diagnostically relevant stains
for HNSCC, 138–139
Implant fabrication, of porous space maintainers for
staged mandibular reconstruction, 145
Incidence, of head and neck cancers, 123–124
Infections, of head and neck, MRI in diagnosis
of, 254, 257–260
Intensity-modulated radiation therapy, 224
Jaw bone necrosis. See Osteonecrosis of the jaw.
Leukoplakia, as precursor of HNSCC, 126–128
proliferative verrucous, 128
Lichen planus, oral, as precursor of HNSCC, 128
Lymph node metastases, in histologic grading of
HNSCC, 137–138
Lymphoma, of the jaws, chemotherapy for, 167
Magnetic resonance imaging (MRI), in diagnosis of
head and neck disease, 253–269
brachial plexus, 267
infections, 254, 257–260
neoplasms and masses, 254–257
skull base and temporal bones, 260–261
vascular lesions, 260, 262–266
in evaluation of neck for nodal metastases, 214–216
Mandibular reconstruction, staged, use of porous
space maintainers in, 143–149
advantages of, 144–145
case series, 145–146
clinical challenge, 143–144
clinical outcomes, 146–148
implant fabrication, 145
technical innovations, 144
Margins. See Surgical margins.
Masses, of head and neck, MRI in diagnosis of, 254–257
Maxillofacial tumors. See also Head and neck
pathologies.
chemotherapy for, 163–169
Metabolic disorders, bisphosphonates in, 233
Metastatic disease, chemotherapy for, 165–166
Molecular alterations, as prognostic markers for
HNSCC, 139
Mouth, floor of, as site of HNSCC, 126
Mucositis, during antineoplastic therapy, 198–199
Multiple myeloma, bisphosphonates in, 232–233
Myelosuppression, during antineoplastic therapy, 198
Neck. See also Head and neck.
evaluation and staging of in patients with
malignant disease, 209–221
carcinoma of unknown primary, 213–214
considerations for N staging, 211–212
evaluation for nodal metastases, 214–218
CT and MRI, 214–216
during post-therapeutic surveillance,
217–218
PET/CT, 216–217
sentinel lymph node biopsy, 217
ultrasound, 214
salivary gland cancers, 213
squamous cell carcinoma, 212–213
TNM classification and staging, 210–211
Neoadjuvant chemotherapy, for locally advanced
resectable oral and maxillofacial tumors, 164
Neoplasms, of head and neck, MRI in diagnosis of, 254–257
Neurotoxicity, during antineoplastic therapy, 199–200
Nuclear medicine imaging, in diagnosis of head and
neck disease, 239–245
introduction to PET/CT imaging, 239–241
PET imaging in drug-induced osteonecrosis of
the jaw, 243
technical aspects of PET imaging, 241–242
typical images, 242–243
Oral epithelial dysplasia, evaluation of, 131–133
Oral lichen planus, as precursor of HNSCC, 128
Oral submucous fibrosis, as precursor of HNSCC, 128
Oral surgery, in patients undergoing chemoradiation therapy, 193–207
after chemoradiation therapy, 200–201
dental implant placement, 203–205
oral surgery in irradiated jaws, 202
prevention and treatment of osteonecrosis of jaw bone, 201–202
prophylactic hyperbaric oxygen therapy, 202–203
trismus, 200–201
chemotherapy, 194
epidemiology, 194
patient management during, 198–200
mucositis, 198–199
myelosuppression, 198
neurotoxicity and taste alteration, 199–200
xerostomia, 200
preparations before start of therapy, 195–198
in patients receiving chemotherapy, 195
in patients receiving radiation therapy, 195–198
radiation therapy, 194–195
pitfalls in determining head and neck surgical margins, 151–162
assessment of, 152–158
anatomic and histologic margins, 152–154
bone margins, 155–156
excision method, 157
good margins, 157
margin reporting, 157–158
measurements, 152
techniques for pathologic, 155
tissue shrinkage, 156–157
tumor mapping with pathologist, 154–155
future directions, 158–159
historical perspective, 151–152
oral cavity cancer epidemiology, 152
therapeutic implications of positive margins, 158
Oral tumors. See also Head and neck pathologies.
chemotherapy for, 163–169
Osteonecrosis of the jaws, anti-resorptive, 171–191
higher incidence of in patients with cancer, 174–177
in patients without cancer naive to anti-resorptive medications, 172–174
reconstruction of mandibular segmental defects, 184–188
resection as first-line therapy for, 180–184
risk to tori and exostoses, 177–180
bisphosphonate-related, 171–191
drug-induced, PET imaging in, 243–244
prevention and treatment of, 201–205
classification and treatment, 203
dental implant placement after radiation therapy to head and neck, 203–205
oral surgery in irradiated jaws, 202
prophylactic hyperbaric oxygen therapy, 202–203
Osteoradionecrosis of the jaw, pharmacologic modalities in treatment of, 247–252
hyperbaric oxygen therapy, 249–250
pathogenesis, 247–249
pentoxyfilline and tocopherol, 250
with or without clodronate, 250–251
Osteosarcoma, of head and neck, chemotherapy for, 166–167
P
p16, as prognostic biomarker for HNSCC, 138–139
Pan, as risk factor for HNSCC, 124
Pentoxyfilline, for treatment of osteonecrosis of the jaw, 250
combined with tocopherol with or without clodronate, 250–251
Plummer-Vinson syndrome, as risk factor for HNSCC, 125
Positron emission tomography (PET), in diagnosis of head and neck disease, 239–245
introduction to PET/CT imaging, 239–241
PET imaging in drug-induced osteonecrosis of the jaw, 243
technical aspects of PET imaging, 241–242
typical images, 242–243
Positron emission tomography (PET), in evaluation of neck for nodal metastases, 216–217
Precursor lesions, of HNSCC, 126–129
erthroplakia, 129
leukoplakia, 126–128
oral lichen planus, 129
oral submucous fibrosis, 129
proliferative verrucous leukoplakia, 128
Prognostic indicators, in HNSCC, 133–139
biomarkers, 138–139
biopsy, 133
histologic prognosticators, 136–138
histologic subtypes, 133–136
immunohistochemistry, 138
molecular alterations, 139
R
Race, and increasing predilection to HNSCC, 125–126
Radiation therapy, for oral and maxillofacial tumors, 223–229
for locally advanced unresectable, 164–165
induction chemotherapy before concurrent chemoradiation, 165
induction chemotherapy before, versus radiation alone, 164
techniques for, 223–227
toxicity from, 227–228
Radiation-induced osteonecrosis, of jaw, pharmacologic treatment of, 247–252
RANKL inhibitor medications, osteonecrosis of the jaws related to, 171–191
Reconstruction, staged mandibular, use of porous space maintainers in, 143–149
advantages of, 144–145
case series, 145–146
clinical challenge, 143–144
clinical outcomes, 146–148
implant fabrication, 145
technical innovations, 144
Response to treatment, predictors of, in HNSCC, 133–139
Risk factors, for HNSCC, 124–125
HPV, 124–125
other contributing factors, 125
tobacco and alcohol, 124
Salivary gland cancers, evaluation and staging of neck in patients with, 213
Sentinel lymph node biopsy, in evaluation of neck for nodal metastases, 217
Skull base, MRI in diagnosis of conditions of, 260–261
Space maintainers, porous, in staged mandibular reconstruction, 143–149
Squamous cell carcinoma, evaluation and staging of neck in patients with, 212–213
oral and maxillofacial, chemotherapy for, 163–169
Staging, of neck in patients with malignant disease, 210–212
considerations for N staging, 211–212
TNM classification and, 210–211
tumor, in HNSCC, 138
Surgery. See Oral surgery.
Surgical margins, in histologic grading of HNSCC, 137
pitfalls in determining head and neck, 151–162
assessment of, 152–158
anatomic and histologic margins, 152–154
tissue shrinkage, 155–156
bone margins, 155–156
excision method, 157
good margins, 157
tumor mapping with pathologist, 154–155
future directions, 158–159
historical perspective, 151–152
oral cavity cancer epidemiology, 152
therapeutic implications of positive margins, 158
Survival, post-therapeutic, evaluation of neck during, 217–218
Targeted therapy, for metastatic or recurrent oral and maxillofacial tumors, 186
Taste alteration, during antineoplastic therapy, 199–200
Temporal bones, MRI in diagnosis of conditions of, 260–261
TNM classification, and staging of neck in patients with malignant disease, 210–211
Tobacco, as risk factor for HNSCC, 124
Tocopherol, for treatment of osteonecrosis of the jaw, 250
combined with pentoxyfilline with or without clodronate, 250–251
Tongue, HNSCC of, 126
Tp53, as prognostic marker for HNSCC, 139
Trismus, after chemoradiation therapy, 200–201
Ultrasonography, in evaluation of neck for nodal metastases, 214
Ultrasonography, in evaluation of neck for nodal metastases, 214
Vascular lesions, head and neck, MRI in diagnosis, 260, 262–266
Xerostomia, during antineoplastic therapy, 200